Literature DB >> 15108012

Value and limits of immunohistochemistry in differential diagnosis of clear cell primary brain tumors.

Oskar Koperek1, Ellen Gelpi, Peter Birner, Christine Haberler, Herbert Budka, Johannes A Hainfellner.   

Abstract

Clear cell histology is the hallmark of oligodendroglioma (OG) but also characterizes clear cell ependymoma (CCE) and central neurocytoma (CN). Immunohistochemistry for glial and neuronal proteins may support differential diagnosis. We investigated systematically diagnostic value and limits of immunohistochemistry using representative tumor specimens (>1 cm in diameter) of well-defined OGs, CCEs, and CNs (n=10, respectively). Antibodies comprised anti-neuron specific nuclear protein (NEUN), anti-synaptophysin, anti-neuron-specific enolase, anti-microtubule-associated protein 2, anti-phosphorylated neurofilament protein, anti-non-phosphorylated neurofilament protein, anti-glial fibrillary acidic protein (GFAP), anti-S100 protein, anti-vimentin (VIM), and anti-epithelial membrane antigen (EMA). Among the panel of antibodies anti-NEUN, anti-VIM and anti-EMA proved most useful for differential diagnosis. Prominent (>90%) anti-NEUN immunolabeling of tumor cells clearly distinguished CNs from OGs and CCEs. Anti-VIM immunolabeling and a characteristic cytoplasmic dot-like anti-EMA immunoreactivity pattern of tumor cells were detectable only in OGs and CCEs. Furthermore, prominent anti-VIM immunoreactivity and anti-EMA cell membrane staining including ring-like staining pattern is characteristic for CCEs. Additionally, a widespread gliofibrillary and minigemistocytic cytoplasmic anti-GFAP immunostaining pattern is restricted to some OGs. Our data indicate that immunohistochemistry using anti-NEUN, anti-VIM, and anti-EMA on representative tumor specimens allows clear-cut distinction of CNs vs OGs and CCEs. Anti-VIM, anti-EMA, and anti-GFAP support differential diagnosis of OGs vs CCEs. Nevertheless, it is noted that due to focal expression of glial proteins in CNs and, conversely, of neuronal proteins in OGs and CCEs, immunohistochemistry is of limited value on small tumor specimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15108012     DOI: 10.1007/s00401-004-0856-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  4 in total

Review 1.  Central Neurocytoma: A Review of Clinical Management and Histopathologic Features.

Authors:  Seung J Lee; Timothy T Bui; Cheng Hao Jacky Chen; Carlito Lagman; Lawrance K Chung; Sabrin Sidhu; David J Seo; William H Yong; Todd L Siegal; Minsu Kim; Isaac Yang
Journal:  Brain Tumor Res Treat       Date:  2016-10-31

2.  Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.

Authors:  Minna Niittykoski; Mikael von Und Zu Fraunberg; Miika Martikainen; Tuomas Rauramaa; Arto Immonen; Susanna Koponen; Ville Leinonen; Markus Vähä-Koskela; Qiwei Zhang; Florian Kühnel; Ya-Fang Mei; Seppo Ylä-Herttuala; Juha E Jääskeläinen; Ari Hinkkanen
Journal:  Transl Oncol       Date:  2017-08-04       Impact factor: 4.243

3.  Intramedullary clear cell ependymoma of the lower thoracic spinal cord: report of a new case.

Authors:  Jesus Rocha-Maguey; Jesus Salvador Velarde-Felix; Myriam Cabrera-Lopez; Jaime Moya-Nuñez; Edgar Fragosa-Sanchez
Journal:  Surg Neurol Int       Date:  2020-12-11

4.  Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma.

Authors:  Emmanuel Rousseau; Thomas Palm; Francesco Scaravilli; Marie-Magdeleine Ruchoux; Dominique Figarella-Branger; Isabelle Salmon; David Ellison; Catherine Lacroix; Françoise Chapon; Jacqueline Mikol; Miikka Vikkula; Catherine Godfraind
Journal:  Mol Cancer       Date:  2007-07-12       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.